Get the Stockscreener App
0.71
81.59%
0.319
Equillium Inc stock is traded at $0.71, with a volume of 142.99M.
It is up +81.59% in the last 24 hours and up +125.40% over the past month.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
See More
Previous Close:
$0.391
Open:
$0.4
24h Volume:
142.99M
Relative Volume:
50.22
Market Cap:
$25.36M
Revenue:
$45.91M
Net Income/Loss:
$-4.62M
P/E Ratio:
-5.0642
EPS:
-0.1402
Net Cash Flow:
$-21.51M
1W Performance:
+76.31%
1M Performance:
+125.40%
6M Performance:
+10.94%
1Y Performance:
-2.77%
1-Day Range:
$0.3702
$1.36
1-Week Range:
$0.37
$1.36
52-Week Range:
$0.27
$1.50
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
0.71 | 13.97M | 45.91M | -4.62M | -21.51M | -0.1402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
Multi factor analysis applied to Equillium Inc.Trade Ideas Based on Fundamental Metrics - Newser
Ranking Equillium Inc. among high performing stocks via toolsMulti-Year Investment Performance Summary Report - Newser
How high can Equillium Inc. stock goFree Low Risk Equity Screener With Results - Newser
What is the risk reward ratio of investing in Equillium Inc. stockBest Dividend Review For Consistent Profits - jammulinksnews.com
How to track smart money flows in Equillium Inc.Free Oversold Bounce Stock Play Ideas - Newser
What institutional investors are buying Equillium Inc. stockMarket Forecast Planner With Proven Results - jammulinksnews.com
Combining price and volume data for Equillium Inc.Buy Zone Strategy with Pattern Recognition - Newser
How does Equillium Inc. generate profit in a changing economyWealth Building Picks That Work - jammulinksnews.com
Why Equillium Inc. stock attracts strong analyst attentionFree Fundamental Winners With Safe Entry Plan - Newser
What makes Equillium Inc. stock attractive to long term investorsVolume Spike Detection for Early Breakouts - Newser
When is Equillium Inc. stock expected to show significant growthChart Pattern Opportunities With High Returns - jammulinksnews.com
Historical volatility pattern of Equillium Inc. visualizedSector Rotation Strategy for Smart Traders - Newser
Should you hold or exit Equillium Inc. nowFree Capital Efficiency Optimized Stock Alerts - Newser
Will Equillium Inc. stock go up soonFree Smart Money Tracking Signal Generator - Newser
Can Equillium Inc. rally from current levelsSmart Entry Watchlist with Daily Analysis - Newser
Equillium Inc. Stock Performance After Earnings: Historical InsightsTrading Volume Spike and Reversal Analysis - Newser
Is It Too Early to Call Recovery in Equillium Inc.Swing Trading Plan With Smart Signals in Review - metal.it
What makes Equillium Inc. stock price move sharplyFree High-Accuracy Stock Picks - beatles.ru
What machine learning models say about Equillium Inc.Market Correction Proof Stock Screening Analysis - Newser
Equillium Inc. Chart Enters High Volatility ZoneEntry Alert With Low Drawdown Strategy Noted - metal.it
Will Equillium Inc. Recover After Recent DeclineSecure Return Focused Investment Plan Released - metal.it
Equillium Inc (EQ) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Chart Analysts Warn of Resistance Near Equillium Inc. PriceMarket Surge Signal for Swing Traders Triggered - beatles.ru
Is Equillium Inc. stock entering bullish territoryPredictive Model for Intraday Swing Forecast - Newser
Why is Equillium Inc. stock attracting strong analyst attentionFree Trading Psychology Coaching - jammulinksnews.com
How volatile is Equillium Inc. stock compared to the marketCapitalize on emerging market trends - jammulinksnews.com
How strong is Equillium Inc. company’s balance sheetInvest confidently with professional market insights - jammulinksnews.com
Is Equillium Inc. stock overvalued or undervaluedBreakout portfolio performance - jammulinksnews.com
What are analysts’ price targets for Equillium Inc. in the next 12 monthsInvest smarter with data-backed trading alerts - jammulinksnews.com
Is Equillium Inc. stock a good hedge against inflationDaily Gain Forecast - metal.it
Is Equillium Inc. a growth stock or a value stockAccess powerful market insights for free - jammulinksnews.com
What drives Equillium Inc. stock priceUnprecedented growth rates - PrintWeekIndia
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):